

Date: 13.02.2023
Bengaluru

To,
**The Listing Manager,
Bombay Stock Exchange Limited,
25th Floor, PJ Towers,
Dalal Street,
Mumbai-400001**

Dear Sir / Madam,

Sub: Outcome of Board Meeting held on 13.02.2023

A. This is to inform that the Board of the Directors at their meeting held today, i.e. Monday, February 13, 2023, have:

Approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended December 31, 2022.

B. The Board Meeting commenced at 03.00 PM and concluded at 05.45 PM.

Kindly take the aforesaid information on record in compliance of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015.

Thanking You.

Yours Faithfully,

For Natural Capsules Limited



Shilpa Burman
Company Secretary & Compliance Officer



**SHILPA
BURMAN** Digitally signed by
SHILPA BURMAN
Date: 2023.02.13
17:45:43 +05'30'

P. CHANDRASEKAR LLP

Chartered Accountants

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

The Board of Directors
Natural capsules Limited
Bangalore – 560011.

1. We have reviewed the accompanying statement of unaudited Standalone financial results ("the Statement") of **Natural Capsules Limited** ("the Company") for the Quarter and Nine Months ended 31st December 2022 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Bangalore
Date: 13th February 2023

For P CHANDRASEKAR LLP
Chartered Accountants
(Firm Regn. No.000580S/S200066)



P. Chandrasekaran
Partner

Membership No. 026037

UDIN - 23026037B4WNVH3259



Bangalore * Chennai

NATURAL CAPSULES LIMITED

TRIDENT TOWERS, 4TH FLOOR, NO. 23, 100 FEET ROAD, JAYANAGAR II BLOCK, BANGALORE-560 011
Ph. 26671571/573, Fax 26671562, E-mail : Info@naturalcapsules.com / CIN: L85110KA1993PLCO14742
UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER / NINE MONTH ENDED DEC 31, 2022.

Rs. In Lacs

Sl. No.	PARTICULARS	Quarter Ended		Nine Months Ended		Year Ended	
		31st Dec 2022	30th Sep 2022	31st Dec 2021	31st Dec 2022	31st Dec 2021	31st March 2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations	4,550	4,506	3,761	13,475	9,352	13,507
2	Other Income	1	4	6	25	20	93
3	Total Income (1+2)	4,551	4,510	3,767	13,500	9,372	13,600
4	Expenses						
	a) Cost of Material consumed	2,181	2,024	1,574	6,284	3,988	5,604
	b) (Increase) / Decrease in stock in trade	-111	-33	15	-217	(63)	181
	c) Purchase of stock-in-trade	49	-	-	49	195	195
	d) Employees benefits expense	280	269	263	812	725	962
	f) Finance cost	95	72	57	229	129	196
	g) Depreciation	174	196	125	533	364	504
	h) Other Expenses	1,181	1,280	1,139	3,693	2,775	4,015
	Total Expenses	3,849	3,807	3,173	11,382	8,114	11,657
5	Profit from ordinary activities after finance costs but before exceptional items	702	703	594	2,118	1,257	1,943
6	Exceptional Items Income / (Expenses)	-	-	-	-	-	-
7	Profit from ordinary activities before tax	702	703	594	2,118	1,257	1,943
8	Tax Expense						
	- Current Tax	177	169	181	535	371	547
	- Income tax (Prior year)	167	156	165	490	325	474
	- Deferred Tax	10	13	17	45	46	73
9	Net Profit (+) / Loss (-) from ordinary activities after tax	525	534	413	1,583	886	1,395
10	Other Comprehensive income (OCI)						
	a) Items that will not be reclassified to profit or loss (net of tax)	-	-	-	-	-	(20)
	b) Items that will be reclassified to profit or loss (net of tax)	-	-	-	-	-	-
11	Total Comprehensive Income (OCI) for the period	525	534	413	1,583	886	1,376
12	Paid-Up Equity Share Capital (face value per share Rs.10/-)	924	777	701	924	701	701
13	Earnings Per Share of (before & after extraordinary items) Rs. 10/-						
	(a) Basic	5.68	6.87	5.89	17.13	12.64	19.62
	(b) Diluted	5.68	6.87	5.89	17.13	12.64	19.62



Note:

1 The unaudited standalone financial results of the Company for the Quarter / Nine Months Ended 31st Dec, 2022 have been approved by the Board of Directors of the Company at its meeting held on 13th February 2023. The figures for the quarter / nine months ended 31st Dec, 2022 was subject to "Limited Review" by the Statutory Auditors of the Company who have expressed an unqualified review opinion.

2 The unaudited standalone financial results for the Quarter / Nine months ended 31st Dec, 2022 have been prepared above in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules 2016. The above unaudited standalone Financial results are filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchange Website.

3 The Company vide letter of offer dated 30th Oct, 2021 issued second & final call notice to existing shareholders as on record date 10.11.2022. Call money period was open from 21.11.2022 to 05.12.2022. Total 31,16,350 Rights equity shares of face value of Rs. 10.00 (of which Rs.5,000/- being called up) ("Rights Equity Shares") at an issue Price of Rs. 100.00 per Equity Share (including a premium of Rs.90 per share and of which Rs. 50 being called up). The Company has received Rs. 44.02 Lakhs on 01.10.2022 against the first call application money-Reminder Notice & Rs. 14.64 cr. on 11.01.2023 towards second & Final call money. The company has already received Rs.779.09 lakh as right issue application money of Rs.25 per rights equity shares (including premium of Rs.22.50 per share) during the quarter ended 31.03.2022 & Rs.708.02 Lakh during the quarter ended 30th Sept against the first call money. There is no deviation in the use of proceeds from the objects stated in the offer documents for the rights issue

4 Utilization of right issue funds by the Natural Capsules Ltd as on 31st Dec, 2022 is as follows: (Rs. In Lakh)

Particulars	
Amount received	1,531.14
Amount Spent	1,530.10
Balance available as on 31.12.2022	1.04

5 Previous years figures have been regrouped wherever necessary.

6 Position of investor complaints for the quarter ended 31st Dec, 2022

Particulars

Received during the quarter

Resolved during the quarter

Pending as on 31-12-2022

Place : Bangalore

Date : 13-02-2023

1
1
Nil



Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To
The Board of Directors
Natural Capsules Limited
Bangalore- 560011.

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Natural Capsules Limited** ("the parent") and its Subsidiaries(the parent and its subsidiaries together referred to as "the group") for the Quarter ended 31st December 2022 and year to date results for the period from 01 April 2022 to 31st December 2022 , being submitted by the parent pursuant to the requirements of Regulation 33 of SEBI (Listing obligations and Disclosure requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Parent's Management and has been approved by the Parents Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting standard 34 "Interim Financial Reporting"("Ind AS 34"), prescribed under section 133 of companies act,2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of the Entity	Relationship
Natural Phyto Pharma Private Limited	Subsidiary
Natural Biogenex Private Limited	Subsidiary



5. We did not review the interim financial results of one subsidiary included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs. Nil for the nine months ended 31st December 2022 and the total net loss after tax of Rs. 0.10 Lacs for the nine months ended 31st December 2022 as considered in the Statement. These interim financial results have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports furnished by the management. In our opinion and according to the Information and explanations given to us by management, these financial statements and other financial information are not material to the Group. Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the financial information certified by management.
6. Based on our review conducted as above and based on the consideration of the review financial results/financial information certified by the Management as given above in point no.6, nothing has come to our attention that causes us to believe that the Statement, prepared in accordance with applicable Indian accounting standards and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Bangalore
Date: 13th February 2023

For P Chandrasekar LLP
Chartered Accountants
(Firm Regn. No.000580S/S200066)



P. Chandrasekaran
Partner
Membership No. 026037
UDIN: 23026037B6WNU



I6313

NATURAL CAPSULES LIMITED

TRIDENT TOWERS, 4TH FLOOR, NO. 23, 100 FEET ROAD, JAYANAGAR II BLOCK, BANGALORE-560 011

Ph. 26671571/573, Fax 26671562, E-mail : Info@naturalcapsules.com / CIN: L85110KA1993PLC014742

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTH ENDED DEC 31, 2022

Sl. No.	PARTICULARS	Quarter Ended			Nine Months Ended		Year Ended
		31st Dec 2022	30th Sep 2022	31st Dec 2021	31st Dec 2022	31st Dec 2021	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
1	Revenue from operations	4,550	4,506	3,761	13,475	9,352	13,507
2	Other Income	5	7	6	36	20	101
3	Total Income (1+2)	4,556	4,513	3,767	13,511	9,372	13,608
4	Expenses						
	a) Cost of Material consumed	2,181	2,024	1,574	6,284	3,988	5,604
	b) (Increase) / Decrease in stock in trade	(111)	(33)	15	(217)	(63)	181
	c) Purchase of stock-in-trade	49	-	-	49	195	195
	d) Employees benefits expense	280	269	263	812	725	962
	f) Finance cost	95	72	57	229	129	196
	g) Depreciation	174	196	125	534	364	504
	h) Other Expenses	1,185	1,284	1,142	3,707	2,781	4,027
	Total Expenses	3,854	3,812	3,176	11,397	8,121	11,669
5	Profit from ordinary activities after finance costs but before exceptional items	702	702	591	2,114	1,251	1,939
6	Exceptional Items Income / (Expenses)	-	-	591	-	-	-
7	Profit from ordinary activities before tax	702	702	591	2,114	1,251	1,939
8	Tax Expense						
	- Current Tax	177	169	181	535	371	547
	- Income tax (Prior year)	167	156	165	490	325	474
	- Deferred Tax	-	-	-	-	-	-
9	Net Profit (+) / Loss (-) from ordinary activities after tax	525	533	410	1,579	880	1,391
10	Other Comprehensive income (OCI)						
	a) Items that will not be reclassified to profit or loss (net of tax)	-	-	-	-	-	(20)
	b) Items that will be reclassified to profit or loss (net of tax)	-	-	-	-	-	-
11	Total Comprehensive Income (OCI) for the period	525	533	410	1,579	880	1,372
12	Paid-Up Equity Share Capital (face value per share Rs. 10/-)	924	777	701	924	701	701
13	Earnings Per Share of (before & after extraordinary items) Rs. 10/-						
	(a) Basic	5.68	6.85	5.85	17.08	12.55	19.56
	(b) Diluted	5.68	6.85	5.85	17.08	12.55	19.56



Note:

1 The unaudited consolidated financial results of the Company for the Quarter / Nine Months Ended 31st Dec, 2022 have been approved by the Board of Directors of the Company at its meeting held on 13th February, 2023. The figures for the quarter / nine months ended 31st Dec, 2022 was subject to "Limited Review" by the Statutory Auditors of the Company who have expressed an unqualified review opinion.

2 The unaudited consolidated financial results for the Quarter / Nine months ended 31st Dec, 2022 have been prepared above in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules 2016. The above unaudited consolidated Financial results are filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchange Website.

3 The Company vide letter of offer dated 30th Oct, 2021 issued second & final call notice to existing shareholders as on record date 10.11.2022. Call money period was open from 21.11.2022 to 05.12.2022. Total 31,16,350 Rights equity shares of face value of Rs. 10.00 (of which Rs.5,00/- being called up) ("Rights Equity Shares") at an issue Price of Rs. 100.00 per Equity Share (including a premium of Rs.90 per share and of which Rs. 50 being called up). The Company has received Rs. 44.02 Lakhs on 01.10.2022 against the first call application money-Reminder Notice & Rs. 14.64 cr. on 11.01.2023 towards second & Final call money. The company has already received Rs.779.09 lakh as right issue application money of Rs.25 per rights equity shares (including premium of Rs.22.50 per share) during the quarter ended 31.03.2022 & Rs.708.02 Lakh during the quarter ended 30th Sept against the first call money. There is no deviation in the use of proceeds from the objects stated in the offer documents for the rights issue

4 Utilization of right issue funds by the Natural Capsules Ltd as on 31st Dec, 2022 is as follows: (Rs. In Lakh)

Particulars

Amount received

1,531.14

Amount Spent

1,530.10

Balance available as on 31.12.2022

1.04

5 Previous years figures have been regrouped wherever necessary.

6 Position of investor complaints for the quarter ended 31st Dec, 2022

Particulars

Received during the quarter

1

Resolved during the quarter

1

Pending as on 31-12-2022

Nil

Place : Bangalore

Date : 13-02-2023

